Does Medicare Cover GLP-1 Weight-Loss Drugs Now? The CMS Bridge Program, Explained

For years, the flat answer to “does Medicare cover Wegovy or Zepbound for weight loss” was no. The Medicare Modernization Act of 2003 specifically excluded “agents when used for anorexia, weight loss, or weight gain” from Part D. That exclusion is still federal law. What changed on July 1, 2026 is narrower than a law change: CMS launched a temporary demonstration, the Medicare GLP-1 Bridge, that provides access to specific GLP-1 drugs outside the normal Part D coverage rules. If you’re comparing what a Houston clinic charges out of pocket against what a patient on Medicare might now pay, this is the program to understand — and its limits matter as much as its existence.

What the Bridge actually is

CMS isn’t claiming new coverage authority here. The Medicare GLP-1 Bridge runs under the Secretary’s existing demonstration authority — Section 402(a)(1)(A) of the Social Security Amendments of 1967, as extended to Part D — to test whether a different payment approach improves efficiency. It’s explicitly temporary: July 1, 2026 through December 31, 2027. It also runs outside the normal Part D payment flow entirely. Part D plans don’t have to opt in, don’t carry the financial risk, and a single CMS-designated central processor handles prior authorization, claims, and pharmacy payment instead of your regular plan. CMS says the Bridge was extended through the full 2027 window in part because a planned successor model, called BALANCE, didn’t launch as scheduled — the Bridge is filling that gap while CMS collects usage data.

Which drugs, and what it costs

The program covers three specific products: Foundayo (tablet), Wegovy (injection or tablet), and Zepbound (KwikPen only — single-dose vials and pens don’t qualify). Ozempic and Mounjaro, the same molecules marketed for type 2 diabetes, aren’t on that list. Eligible beneficiaries pay $50 for a month’s supply. Because the drug is furnished outside the standard Part D benefit, the usual Part D deductible doesn’t apply to it, the $50 doesn’t count toward true out-of-pocket (TrOOP) spending, and beneficiaries who get the Part D low-income subsidy don’t get an additional subsidy on top of the $50 — it’s a flat rate regardless.

Who actually qualifies

Eligibility runs on the same tiered BMI-plus-condition structure the obesity field already uses, not a simple “have Medicare” test. You must be 18 or older and meet one of three thresholds: a BMI of 35 or higher on its own; a BMI of 30 or higher plus at least one of heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease at stage 3a or higher; or a BMI of 27 or higher plus prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. You’re not eligible if a Part D plan is already covering a GLP-1 for you, and — notably — having type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease on its own doesn’t qualify you for the Bridge, though your existing Part D plan may already cover a GLP-1 for one of those diagnoses on a separate basis. Getting the drug still requires your provider to submit a prior authorization certifying the medication is part of a diet-and-exercise program — this isn’t a walk-in, no-questions purchase.

Why this matters even if you’re not on Medicare

None of the clinics in this directory bill Medicare for GLP-1 prescriptions the way a Part D pharmacy claim works — patients here are typically paying the clinic directly, and the Bridge program’s $50 flows through a pharmacy claim, not a clinic invoice. But the program is still a useful reference point when you’re evaluating a price. It only covers three specific, FDA-approved, brand-name products — no compounded version of any of them qualifies, which lines up with the same brand-vs-compounded distinction we cover in our breakdown of legal sourcing. If a clinic’s pricing pitch leans on “insurance-equivalent” savings for a compounded product, the Bridge is a concrete example of what federal programs actually treat as legitimate — and it isn’t compounded semaglutide or tirzepatide.

See our full verification standard for how we screen clinics before listing them, and browse verified GLP-1 and peptide clinics in Houston.

---

Sources: Centers for Medicare & Medicaid Services, “Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries”, published May 6, 2026. CMS, “Medicare GLP-1 Bridge” FAQ page, page last modified July 13, 2026 — demonstration authority, dates, and copay/TrOOP mechanics. Medicare.gov, “Weight loss drugs” — eligibility tiers, covered drug list, and prior-authorization requirement, verified current September 18, 2026.

This article is independent editorial content, not medical or financial advice. See our medical disclaimer.